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Available online 30 May 2016Background: Advanced brain MR techniques are useful tools for differentiating Progressive Supranuclear Palsy
from Parkinson's disease, although time-consuming and unlikely to be used all together in routine clinical
work. We aimed to compare the diagnostic accuracy of quantitative morphometric, volumetric and DTI metrics
for differentiating Progressive Supranuclear Palsy-Richardson's Syndrome from Parkinson's disease.
Methods: 23 Progressive Supranuclear Palsy-Richardson's Syndrome and 42 Parkinson's disease patients
underwent a standardized 1.5T brain MR protocol comprising high-resolution T1W1 and DTI sequences.
Brainstem and cerebellar peduncles morphometry, automated volumetric analysis of brain deep gray matter
and DTI metric analyses of speciﬁc brain structures were carried out. We determined diagnostic accuracy, sensi-
tivity and speciﬁcity of MR-markers with respect to the clinical diagnosis by using univariate receiver operating
characteristics curve analyses. Age-adjusted multivariate receiver operating characteristics analyses were then
conducted including only MR-markers with a sensitivity and speciﬁcity exceeding 80%.
Results:Morphometricmarkers (midbrain area, pons tomidbrain area ratio andMRParkinsonism Index), DTI pa-
rameters (infratentorial structures) and volumetric analysis (thalamus, putamen and pallidus nuclei) presented
moderate to high diagnostic accuracy in discriminating Progressive Supranuclear Palsy-Richardson's Syndrome
from Parkinson's disease, with midbrain area showing the highest diagnostic accuracy (99%) (mean ± standard
deviation: 75.87 ± 16.95 mm2 vs 132.45 ± 20.94 mm2, respectively; p b 0.001).
Conclusion: Although several quantitative brain MRmarkers provided high diagnostic accuracy in differentiating
Progressive Supranuclear Palsy-Richardson's Syndrome from Parkinson's disease, the morphometric assessment
of midbrain area is the best single diagnostic marker and should be routinely included in the neuroradiological
work-up of parkinsonian patients.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The in vivo differential diagnosis between Progressive Supranuclear
Palsy-Richardson's Syndrome (PSP-RS) and idiopathic Parkinson's Dis-
ease (PD) may be difﬁcult (Williams and Lees, 2009; Mahlknecht et
al., 2010). Speciﬁc alterations at conventional brain MR, such as mid-
brain and superior cerebellar peduncles (SCP) atrophy, may contribute
to the diagnosis of PSP (Mahlknecht et al., 2010; Stamelou et al.,
2011), despite their lack of accuracy (Schrag et al., 2000; Mahlknecht
et al., 2010; Massey et al., 2012). The retrospective analysis of conven-
tional brain MR in 22 pathologically conﬁrmed PSP showed that thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tients with 100% speciﬁcity but a sensitivity lower than 70% (Massey et
al., 2012).
Considering the lack of sensitivity of conventional brain MR, ad-
vanced neuroimaging techniques have been used to increase diagnostic
accuracy quantifying in vivomacro- and micro-structural abnormalities
of speciﬁc brain regions typically involved in PSP neuropathology.
Volumetric and morphometric analysis of basal ganglia, brainstem
and cerebellum, alongwith diffusion imaging techniques, showedmod-
erate to high diagnostic accuracies in differentiating atypical parkinson-
isms from PD, and in particular PSP (Schulz et al., 1999; Cordato et al.,
2002; Seppi et al., 2003; Oba et al., 2005; Paviour et al., 2005; Paviour
et al., 2006; Nicoletti et al., 2008; Quattrone et al., 2008; Rizzo et al.,
2008; Mahlknecht et al., 2010; Wang et al., 2010; Longoni et al., 2011;
Morelli et al., 2011; Stamelou et al., 2011; Tsukamoto et al., 2012;
Nicoletti et al., 2013; Prodoehl et al., 2013).
Although different quantitativeMR techniquesmay clearly provide a
substantial contribution to the differential diagnosis of degenerative
parkinsonisms, these techniques are demanding in terms of acquisition
time and post-acquisition analysis and unlikely to beused all together in
the study of a single patient in the clinical routine. In this study, for the
ﬁrst time, we have compared the diagnostic accuracy of multiple quan-
titative brain MR markers in the same population of patients PSP-RS or
PD, in order to identify one or more MR markers that best differentiate
these two parkinsonisms.2. Methods
2.1. Subjects
This retrospective study included 23 consecutive patients with PSP-
RS and 42 consecutive patients with PD who underwent brain MR be-
tween 2010 and 2014 as part of their diagnostic workup.
Diagnosis was performed by neurologists with experience in move-
ment disorders (SZ, GC-B,MG, PDM, PC) according to current diagnostic
criteria (Litvan et al., 1996; Gelb et al., 1999; Williams and Lees, 2009).
All patients with a diagnosis of PSP-RS or PD were included. Demo-
graphic and clinical features of PSP-RS and PD patients are summarized
in Table 1. Clinical data were obtained from patients and from clinical
records collected on the day of the MR scan, at which time 19 patients
fulﬁlled criteria for possible PD and 23 for probable PD, 1 patientwas di-
agnosed as possible PSP-RS and 22 as probable PSP-RS. Because some
subjects underwent MR scan years before the re-examination of the
data, in all possible PD patients, diagnosis evolved to probable PD. All
subjects gave consent to personal data processing for research purposes
and the protocol was approved by the local Ethical Committee.Table 1
Demographic and clinical features of PSP-RS and PD patients at the time of brain MR scan.
PSP-RS
N 23
Age at evaluation (years) [mean (SD)] 72.8 (7.1)
Sex [male/female] 12/11
Disease duration (years) [mean (SD) – (range)] 4.2 (2.69)
Hoehn-Yahr's modiﬁed scale Stage (percentage frequency) 1 0%
1.5 0%
2 0%
2.5 0%
3 47%
4 53%
5 0%
Legend: PSP-RS: Progressive Supranuclear Palsy-Richardson's Syndrome; PD: Idiopathic Parkin
§ Independent-sample t-test.
° χ2 test.
^ Mann-Whitney test.2.2. MRI protocol acquisition
Brain MR studies were performed using a 1.5 Tesla GE Medical Sys-
tems Signa HDx 15 system equipped with a quadrature birdcage head
coil. Structural imaging included coronal FLAIR T2WI (repetition time,
TR = 8000 ms, inversion time, TI = 2000 ms, echo time, TE =
93.5 ms, 3 mm slice thickness with no inter-slice gap), FSE axial T2WI
(TR=7000ms, TE= 100ms, 3mm slice thickness), and 3D volumetric
T1WI fast spoiled gradient-echo (FSPGR) images (TR = 12.5 ms, TE =
5.1ms, TI= 600ms, 25.6 cm2 FOV; 1 mm isotropic voxels). We also ac-
quired axial DTI images of contiguous 3 mm slices using a single-shot
SE-EPI sequence with TE = 85.4 ms; TR = 10 s; FOV = 32 × 32 cm,
in-plane resolution = 128 × 128, 25 diffusion-weighted directions
and 7 unweighted scans, b-value = 900 s/mm2. The total acquisition
time was about 27 min.
MR images obtained from each subject were visualized by an expert
neuroradiologist (RL) in order to exclude secondary causes of parkin-
sonism or other abnormalities. All quantitative measurements, such as
morphometric, histogram and ROI analyses, were performed by experts
in neuroimaging (RL, CaT, SZ) blinded to patients' diagnoses.2.3. Morphometric analysis
Morphometric measurements were performed on 3D T1-weighted
volumetric images according to previously reported methods (Oba et
al., 2005). Mean sagittal middle cerebellar peduncle (MCP) diameter,
mean coronal SCP diameter, pons and midbrain areas, MCP/SCP ratio,
pons to midbrain (P/M) ratio, and MR Parkinsonism Index (MRPI)
were calculated (Fig. 1) (Quattrone et al., 2008).2.4. DTI analysis
Mean Diffusivity (MD) and Fractional Anisotropy (FA) values were
calculated in the following ROIs, that were manually selected on T2WI
(b = 0) EPI images: medulla, dentate nucleus, pons, MCP, cerebellar
white matter, SCP, midbrain (decussation of SCPs), posterior limb of in-
ternal capsule, thalamus, globus pallidus, putamen, head of caudate,
parieto-occipital and pre-frontal white matter, genu and splenium cor-
pus callosum (Fig. 1). In order to achieve a more global evaluation of
median brain DTI parameter values, we created MD and FA histograms
of the following structures: brainstem, cerebellar hemispheres, vermis,
posterior fossa, brain hemispheres (Fig. 1).
For all symmetrical structures, with the exception of brain hemi-
spheres,MD, FA and histograms valueswere calculated asmeans orme-
dians of the values obtained on the right and left sides.PD p-value
42
64.7 (10.5) p = 0.001§
29/13 p = 0.18°
– (10 months–10 years) 4.0 (3.3) – (6 months–15 years) p = 0.32§
13% p b 0.001^
0%
26%
26%
33%
2%
0%
son's disease; SD: standard deviation.
Fig. 1. Examples of quantitative brain MR markers. A. manual morphometric
measurement of midbrain and pons area on sagittal 3D T1WI in a patient with
Progressive Supranuclear Palsy-Richardson's Syndrome (PSP-RS); B. DTI histograms
analysis for right (yellow mask on axial T2WI) and left (orange mask on axial T2WI)
brain hemispheres in a PSP-RS patient; C. DTI ROIs analysis: bilateral manual selection of
thalamus (red), posterior limb of the internal capsule (orange), globus pallidus (dark
yellow), putamen (green) and caudate nucleus head (light yellow) in a patient with
idiopathic Parkinson's Disease (PD); D. automatic bilateral segmentation of subcortical
gray matter (caudate nucleus, thalamus, putamen, globus pallidus, hippocampus)
performed by FIRST software on coronal and axial 3D T1WI in a patient with PD.
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Automatic segmentation of the volumetric images was performed
by using FMRIB's Integrated Registration and Segmentation Tool
(FIRST) to delineate brainstem, nucleus accumbens, caudate, hippocam-
pus, globus pallidus, putamen and thalamus and lateral ventricles. All
evaluated volumeswere corrected by a volumetric scaling factor obtain-
ed by SIENAX, as previously reported (Fig. 1) (Smith et al., 2002).2.6. Statistical analysis
The normality of the distribution of study variableswas examined by
using Shapiro-Wilk test. The gender distribution was comparedbetween groups using Pearson's χ2 -test. Continuous variables were
compared between PSP-RS and PD groups using the independent-sam-
ple t-test or Mann-Whitney U-test, as appropriate. Bonferroni correc-
tion for multiple comparisons of measures belonging to the same
domain was applied to the probability level. Receiver operating charac-
teristics (ROC) curve analysiswas used to analyze the diagnostic accura-
cy in terms of sensitivity, speciﬁcity and area under the curve (AUC,
with 95% asymptotic normal conﬁdence interval) of quantitative MR
parameters.
The optimal cut-off value balancing sensitivity and speciﬁcity was
identiﬁed as the one corresponding to the maximum value of Youden's
index, calculated as [sensitivity+ speciﬁcity− 1]. The clinical diagnosis
based on current criteria for PSP-RS and PD was used as the gold stan-
dard (Litvan et al., 1996; Gelb et al., 1999; Williams and Lees, 2009).
AUC values were interpreted according to Swets (1988) as follows:
0.5 b AUC b 0.7 poor accuracy; 0.7 b AU b 0.9 moderate accuracy;
0.9 b AUC b 1.0 high accuracy, AUC = 1 perfect test. The difference be-
tween AUCs was analyzed using the Z-test and DeLong et al.’s method
for the calculation of the standard error of theAUC (DeLong et al., 1988).
We also examined whether diagnostic accuracy was improved by
using MR variables in combination and adjusting for patients' age
using logistic regression analysis with a forward stepwise procedure.
MR variables with AUC ≥ 0.80 in univariate analyses were included
one at a time in decreasing order of discrimination between PD from
PSP-RS. The forward stepwise procedure stopped when additional var-
iables did not contribute further signiﬁcant information at the p ≤ 0.05
signiﬁcance level. ROC curves were calculated for combinations of vari-
ables in the same domain and across domains using the Stata command
roccomp. Analyses were performed using IBM® SPSS® v.21 and Stata®
v.13.1.
3. Results
Patients' characteristics are summarized in Table 1. PSP-RS patients
showed a higher mean age at evaluation than PD, while disease dura-
tion and gender did not differ signiﬁcantly between groups. Moreover,
the median disease stage of patients with PSP-RS, as assessed by
Hoehn and Yahr's modiﬁed scale, was higher compared to the PD
group (median = 3.5 vs 2.5, respectively). No patients were excluded
from analysis due to suboptimal brain MR quality. No patients showed
brain lesions suggestive of secondary causes of parkinsonism.
Tables 2 and 3 report the comparison of the quantitative MR param-
eters between PSP-RS and PD patients and the diagnostic accuracy of
each parameter, including the cut-off values that provide an optimal
balance of sensitivity and speciﬁcity. The AUC curves of the markers
that best discriminated PSP-RS from PD within each domain are
depicted in Fig. 2.
3.1. Morphometric analysis
We found signiﬁcant differences between PSP-RS and PD patient
groups in all measured morphometric parameters. There was a reduc-
tion of both mean MCP and SCP diameters as well as of mean pons and
midbrain areas in PSP-RS patients compared to PD group (Table 2).
MCP/SCP and P/M ratios and MRPI were signiﬁcantly higher in PSP-RS
compared to PD patients (Table 2). Midbrain area, P/M ratio and MRPI
showed the highest accuracy (≥95%), with sensitivity exceeding 87%
and speciﬁcity exceeding 90% in differentiating PSP-RS from PD patents
(Table 3), midbrain area showing the highest diagnostic accuracy (99%).
3.2. Volumetric analysis
Volumetric analysis showed a signiﬁcantly reduced volume of
brainstem, nucleus accumbens, globus pallidus, putamen and thalamus
in the PSP-RS group compared to PD and a signiﬁcantly increased lateral
ventricular volume (Table 2). Thalamic, putaminal and pallidal volumes
Table 2
Comparisons of quantitative MR parameters between PSP-RS and PD groups. Signiﬁcant comparisons are marked in boldface.
PSP-RSmean
(±SD)
PDmean (±SD) p-value (unpaired t-test or
Mann-Whitney U-test)
Morphometric analysis (Bonferroni-corrected signiﬁcance level = 0.05/7 = 0.0071)
Sagittal MCP diameter (mm) 8.38 (±0.98) 9.39 (±0.91) b0.001
Coronal SCP diameter (mm) 3.29 (±0.89) 4.63 (±1.21) 0.001^
Sagittal MCP diameter/coronal SCP diameter ratio 2.71 (±0.74) 2.12 (±0.41) 0.003^
Pons area (mm2) 470.70 (±41.55) 540.19 (±65.27) b0.001^
Midbrain area (mm2) 75.87 (±16.95) 132.45 (±20.94) b0.001
Pons/midbrain areas 6.47 (±1.37) 4.14 (±0.61) b0.001^
MRPI 17.89 (±7.28) 8.73 (±1.97) b0.001^
DTI MD(x10-3mm2/s)
ROI analysis (Bonferroni-corrected signiﬁcance level = 0.05/17 = 0.0029)
Medulla 0.84 (±0.11) 0.87 (±0.11) 0.453
Nucleus dentatus 0.70 (±0.11) 0.69 (±0.06) 0.313^
Pons 0.86 (±0.08) 0.87 (±0.08) 0.686
MCP 0.73 (±0.12) 0.74 (±0.06) 0.712^
Cerebellar WM 0.68 (±0.04) 0.67 (±0.05) 0.154
SCP 1.00 (±0.17) 0.81 (±0.08) b0.001^
Midbrain (SCP decussation) 0.91 (±0.13) 0.85 (±0.12) 0.060^
Posterior limb of internal capsule 0.72 (±0.06) 0.71 (±0.03) 0.007^
Thalamus 0.86 (±0.06) 0.79 (±0.04) b0.001^
Putamen 0.82 (±0.10) 0.75 (±0.03) b0.001^
Globus pallidus 0.86 (±0.09) 0.77 (±0.07) 0.001^
Caudate (head) 0.83 (±0.13) 0.78 (±0.05) 0.047^
Parieto-occipital WM 0.96 (±0.18) 0.84 (±0.06) b0.001^
Pre-frontal WM 0.95 (±0.16) 0.81 (±0.06) b0.001^
Genu corpus callosum 0.95 (±0.10) 0.94 (±0.08) 0.745
Splenium corpus callosum 0.82 (±0.09) 0.81 (±0.08) 0.645
Mean corpus callosum 0.89 (±0.04) 0.88 (±0.05) 0.217^
Histogram analysis (50th percentile) (Bonferroni-corrected signiﬁcance level = 0.05/6 = 0.0083)
Right brain hemisphere 1.00 (±0.09) 0.90 (±0.06) b0.001^
Left brain hemisphere 0.99 (±0.08) 0.91 (±0.06) b0.001^
Posterior fossa 0.97 (±0.12) 0.85 (±0.05) b0.001^
Brainstem 0.99 (±0.11) 0.89 (±0.06) 0.001^
Vermis 1.19 (±0.24) 1.04 (±0.13) 0.011^
Cerebellar hemispheres 0.89 (±0.09) 0.80 (±0.04) b0.001^
DTI FA
ROI analysis (Bonferroni-corrected signiﬁcance level = 0.05/12 = 0.0041)
Medulla 0.37 (±0.12) 0.37 (±0.08) 0.755
Pons 0.36 (±0.07) 0.37 (±0.06) 0.335
MCP 0.61 (±0.09) 0.61 (±0.08) 0.756
Cerebellar WM 0.41 (±0.12) 0.46 (±0.09) 0.057
SCP 0.54 (±0.10) 0.67 (±0.10) b0.001
Midbrain (SCPs decussation) 0.39 (±0.07) 0.48 (±0.10) b0.001
Posterior limb of internal capsule 0.68 (±0.06) 0.66 (±0.04) 0.684^
Parieto-occipital WM 0.32 (±0.05) 0.39 (±0.06) b0.001
Pre-frontal WM 0.27 (±0.06) 0.32 (±0.05) b0.001
Genu corpus callosum 0.67 (±0.08) 0.67 (±0.08) 0.786^
Splenium corpus callosum 0.76 (±0.07) 0.75 (±0.06) 0.880^
Mean corpus callosum 0.72 (±0.04) 0.71 (±0.05) 0.785
Histogram analysis (50th percentile) (Bonferroni-corrected signiﬁcance level = 0.05/6 = 0.0083)
Right brain hemisphere 0.19 (±0.01) 0.21 (±0.01) b0.001^
Left brain hemisphere 0.19 (±0.01) 0.21 (±0.02) b0.001^
Posterior fossa 0.24 (±0.03) 0.26 (±0.02) b0.001
Brainstem 0.35 (±0.03) 0.38 (±0.03) b0.001
Vermis 0.17 (±0.02) 0.19 (±0.03) 0.002^
Cerebellar hemispheres 0.24 (±0.04) 0.26 (±0.02) 0.002^
Volumetric analysis(mm3) (Bonferroni-corrected signiﬁcance level = 0.05/8 = 0.0063)
Brainstem 31,638 (±3698) 35,907 (±3392) b0.001
Nucleus accumbens 611 (±181) 752 (±151) 0.001
Caudate 4435 (±909) 4743 (±659) 0.021^
Hippocampus 5039 (±748) 5439 (±718) 0.038
Lateral ventricles 23,703 (±8704) 17,104 (±8966) 0.004^
Globus pallidus 1865 (±451) 2352 (±347) b0.001
Putamen 5597 (±807) 6468 (±538) b0.001
Thalamus 8899 (±726) 10,014 (±1028) b0.001
Legend: PSP-RS: Progressive Supranuclear Palsy-Richardson's Syndrome; PD: Idiopathic Parkinson's disease; MCP: middle cerebellar peduncle; SCP: superior cerebellar peduncle; MRPI:
MR parkinsonism index; MD: Mean Diffusivity; FA: Fractional Anisotropy.
^ Mann-Whitney test.
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(83%, 83% and 81%, respectively) with sensitivity and speciﬁcity equal
or higher than 73% and 60%, respectively (Table 3). Moreover, areduction in brainstem and an increase in lateral ventricular volumes
showed moderate accuracy with high sensitivity but low speciﬁcity
(Table 3).
Table 3
Diagnostic accuracy of quantitative MR parameters, arranged in decreasing order of AUC within each domain. Parameters with an AUC N=80% are marked in boldface.
MR parameters AUC (%) Cut-off value⁎ Sensitivity (%) Speciﬁcity (%)
Morphometric analysis
Midbrain area (mm2) 99 ≤102.50 96 98
Pons/Midbrain areas 97 ≥4.79 96 90
MRPI 95 ≥10.67 87 93
Coronal SCP diameter (mm) 84 ≤3.75 81 74
Pons area (mm2) 82 ≤496.50 87 74
Sagittal MCP diameter (mm) 78 ≤8.65 70 83
Sagittal MCP diameter/coronal SCP diameter ratio 73 ≥2.81 43 98
DTI MD (x10-3mm2/s)
ROI analysis
SCP 88 ≥0.94 70 98
Pre-frontal WM 86 ≥0.82 90 69
Thalamus 84 ≥0.83 70 86
Putamen 82 ≥0.77 80 71
Parieto-occipital WM 79 ≥0.86 85 64
Globus pallidus 77 ≥0.80 85 67
Histogram analysis (50th percentile)
Posterior fossa 90 ≥0.90 80 83
Cerebellar hemispheres 86 ≥0.83 85 74
Right brain hemisphere 85 ≥0.91 90 74
Left brain hemisphere 84 ≥0.93 80 74
Brainstem 80 ≥0.90 85 67
DTI FA
ROI analysis
SCP 82 ≤0.61 75 80
Parieto-occipital WM 82 ≤0.31 98 55
Midbrain (SCP decussation) 79 ≤0.45 68 90
Pre-frontal WM 74 ≤0.28 83 65
Histogram analysis (50th percentile)
Right brain hemisphere 88 ≤0.20 75 90
Left brain hemisphere 87 ≤0.21 65 95
Posterior fossa 80 ≤0.25 83 75
Brainstem 76 ≤0.35 83 65
Vermis 74 ≤0.18 68 80
Volumetric analysis
Thalamus 83 ≤9575.34 73 90
Putamen 83 ≤5912.80 93 70
Globus pallidus 81 ≤1969.38 93 60
Brainstem 79 ≤32,262.07 90 60
Lateral ventricles 72 ≥12,544.41 100 48
Nucleus accumbens 71 ≤661.47 78 70
Legend: AUC: area under the curve; MRPI: MR parkinsonism index; MCP: mean cerebellar peduncle; SCP: superior cerebellar peduncle; MD: Mean Diffusivity; FA: Fractional Anisotropy.
⁎ Cut-off value corresponded to the maximum Youden's index value.
Fig. 2. Area under the curve (AUC) of the best markers within each analysis domain
(morphometry, volumetry, DTI ROI, DTI histogram). Legend: SCP: superior cerebellar
peduncle; MD: Mean Diffusivity; FA: Fractional Anisotropy. * indicates the best marker
with AUC that signiﬁcantly (p b 0.05) outperformed all the other variables in
discriminating capacity.
740 S. Zanigni et al. / NeuroImage: Clinical 11 (2016) 736–7423.3. DTI analysis
ROIs analysis showed signiﬁcantly increased MD mean values in
PSP-RS compared to PD for SCP, pre-frontal WM, thalamus, putamen,
parieto-occipitalWMand globus pallidus. FAmeanvalueswere reduced
in the SCP, midbrain (decussation of SCPs), parieto-occipital and pre-
frontal WM (Table 2).
At histograms analysis, PSP-RS patients showed, compared to PD, in-
creased median MD and reduced median FA values in right and left
brain hemispheres, posterior fossa, brainstem, increased median MD
in the cerebellar hemispheres (Table 2) and reduced median FA in cer-
ebellar vermis.
ROC analysis showed a diagnostic accuracy higher than 80% for MD
and FA values of SCP, MD of pre-frontal WM, thalamus and putamen,
FA values of parieto-occipital WM; median MD and FA values of brain
hemispheres and posterior fossa and median MD values of brainstem
and cerebellar hemispheres (Table 3). Moreover, these parameters
showedmoderate to high speciﬁcity and sensitivity, with the exception
of a speciﬁcity lower than 70% for mean pre-frontal white matter mean
MD, median brainstemMD, parieto-occipital WMmean FA and a sensi-
tivity lower than 70% for median left brain hemisphere median FA
(Table 3).
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The ROC analysis of midbrain area, adjusted for age, yielded an AUC
of 0.992 (95% CI= 0.978–1.000). No othermorphometric variables pro-
vided an additional signiﬁcant contribution. Similarly, in each domain,
one marker was sufﬁcient to achieve the maximum discrimination. In
particular, after adjustment for age, the best markers were SCP in the
DTI-MD ROI domain (AUC = 0.948, 95% CI = 0.896–0.999), posterior
fossa in the DTI-MD histogram analysis domain (AUC = 0.900, 95%
CI = 0.823–0.978), SCP in the DTI-FA ROI domain (AUC = 0.898, 95%
CI = 0.821–0.975), right brain hemisphere in the DTI-FA histogram
analysis domain (AUC = 0.879, 95% CI = 0.787–0.971) and thalamus
in the volumetric analysis domain (AUC = 0.838, 95% CI = 0.741–
0.935).
3.5. Diagnostic accuracy using combinations of variables across domains
We carried out a further analysis to determine whether an incre-
mental accuracy could be achieved by using the best discriminators of
each domain, added one at a time in a logistic regression model. As ex-
pected, the model with midbrain area reached an almost perfect dis-
crimination and could not be further improved with the addition of
variables from other domains. However, when midbrain area was not
included, the model with DTI-MD histograms analysis of the posterior
fossa alone provided the best discrimination (AUC = 0.901, 95% CI =
0.824–0.979).
The AUCs obtained using the best discriminating parameters for
each domainwere compared using the Z-test. Results (Table 4) indicate
that the midbrain area signiﬁcantly outperformed all the other vari-
ables, and that none of the others differed from each other in discrimi-
nating capacity.
4. Discussion
To our knowledge, this is the ﬁrst study to compare the sensitivity,
speciﬁcity and diagnostic accuracy of several multimodal MR markers
(morphometric, volumetric and DTI-derived) in the same population
of PSP-RS and PD patients, in order to identify the best diagnostic mark-
er/s to be included in theneuroradiologicalwork-upof parkinsonianpa-
tients. The main differences between PSP-RS and PD groups were
represented by macro- and micro-structural and changes in the basal
ganglia (putamen, pallidus and thalamic nuclei) and in infratentorial
structures such as brainstem, cerebellum and cerebellar peduncles,
reﬂecting the distribution of neuropathology in PSP (Dickson et al.,
2010).
Our ROC analysis demonstrates that morphometric and DTI param-
eters have the best diagnostic accuracy in discriminating between
PSP-RS and PD. Notably, morphometric analysis showed superior diag-
nostic accuracy compared to volumetric or DTI metrics in univariate
analyses. Midbrain area, P/M ratio and MRPI diagnostic accuracies
were higher than 95%, midbrain area being the single MR marker pro-
viding the highest accuracy (99%) in differentiating PSP-RS from PD pa-
tients, followed by P/M ratio (97%) and MRPI (95%). Moreover,
multivariate logistic regression analyses combining measures fromTable 4
p-Values of Z-test comparisons between the AUCs of the best discriminating RM parameters in
DOMAIN TEST
Morphometric analysis A Midbrain area
DTI-MD ROIs analysis B SCP
DTI-MD Histograms analysis C Posterior fossa (50th percentile)
DTI-FA ROIs analysis D SCP
DTI-FA Histograms analysis E Right brain hemisphere (50th percenti
Volumetric analysis F Thalamus
Legend: AUC: Area under the Curve; MD: Mean Diffusivity; ROIs: Regions of Interest; SCP: supdifferent domains showed that midbrain area reached the highest AUC
(0.992) in discriminating PSP-RS from PD, and that the addition of
other morphometric, DTI and volumetric quantitative MR markers did
not increase diagnostic accuracy.
Although our PSP-RS patients presented a longer disease duration,
our results are consistent with those of Quattrone et al., who in 2008
proposed a newmorphometric index (MRPI) for the differential diagno-
sis between PSP and other PS, derived from linear MCP and SCP and
pons and midbrain area measures (Quattrone et al., 2008). They found
a high sensitivity, speciﬁcity and positive predictive value of MRPI
values ≥13.55 (100% for all the three diagnostic properties), of MCP/
SCP ratio ≥ 2.69 (78.8%, 88.9% and 68.4%, respectively) and of P/M
ratio ≥ 4.88 (90.9%, 93.5%, and 81.1%, respectively (Quattrone et al.,
2008). The same group appliedmorphometric analysis to a cohort of pa-
tients with PSP, and probable and possible PD, showing that the M/P
ratio was characterized by a moderate accuracy in distinguishing PSP
from probable or possible PD (86.8% and 88.2% respectively) while
MRPI showed higher accuracy (99.5% and 99.4% respectively) (Morelli
et al., 2011). Also Longoni et al. found high diagnostic accuracy, sensitiv-
ity and speciﬁcity of a P/M ratio ≥ 6.01 (94%, 90% and 96%, respectively)
and anMRPI ≥13.57 (97%, 100% and 92%, respectively) in discriminating
PSP-RS from PD (Longoni et al., 2011). Gama and colleague also found
that midbrain area and SCP diameter smaller than 105 mm2 and
3mm, respectively, predicted PSPwith 95% sensitivity and 80% speciﬁc-
ity (Gama et al., 2010). Hussl et al. found a lower diagnostic accuracy,
compared to others (Quattrone et al., 2008; Morelli et al., 2011), of
both M/P ratio and MRPI in differentiating PSP from PD patients (accu-
racy =87.6% vs 77.3%, respectively) (Hussl et al., 2010).
DTImetrics have beenwidely used in the differential diagnosis of de-
generative parkinsonian syndromes (Mahlknecht et al., 2010). In the
present study increased MD and reduced FA values in SCP showed the
highest diagnostic accuracy (88% and 82%, respectively), with moder-
ate-high sensitivity and speciﬁcity (70% and 98% for MD; 75% and 80%
for FA, respectively), compared with other ROIs considered in our DTI
analysis (Table 3). Our ﬁndings are in line with previous studies show-
ing that ADC values in the SCP had a moderate-high sensitivity and
speciﬁcity in discriminating PSP-RS from PD: 90% and 85%, respectively
in one study (Rizzo et al., 2008), and 100% and 93.3% in another
(Nicoletti et al., 2008).Moreover, we found amoderate to high diagnos-
tic accuracy andmoderate to high sensitivity and speciﬁcity of increased
MD values in thalamus (84%, 70%, 86%, respectively) and pre-frontal
white matter (86%, 90%, 69%, respectively).
In our study, automatic volumetric segmentation of brainstem and
the basal ganglia showed a lower diagnostic accuracy compared tomor-
phometric and DTI analysis. Schulz et al. found a signiﬁcantly reduced
striatal and brainstem volumes in PSP and MSA compared to PD,
allowing 5 out of 6 PSP patients to be discriminated from healthy con-
trols and PD groups (Schulz et al., 1999). Cordato et al. found a signiﬁ-
cant reduction of whole brain and frontal lobe volume and an
increased lateral ventricular volume in PSP compared to PD and healthy
controls, but only frontal lobe volume contributed to the differential di-
agnosis (Cordato et al., 2002).
Possible reasons for the discordance of the results among different
studiesmay be related tomethodological issues, including themoderate
accuracy of clinical criteria used as the gold standard (Respondek et al.,each domain.
A B C D E
0.011
0.011 0.761
0.001 0.158 0.298
le) b0.001 0.213 0.110 0.679
0.001 0.391 0.251 0.924 0.730
erior cerebellar peduncle; FA: Fractional Anisotropy.
742 S. Zanigni et al. / NeuroImage: Clinical 11 (2016) 736–7422013; Adler et al., 2014), and the different acquisition and post-process-
ing MR protocols.
Also in our study, the lack of neuropathological conﬁrmation of the
diagnosis could lead to a misclassiﬁcation of patients, in particular
some patients classiﬁed as PD could be PSP-parkinsonism variant.
Moreover, the relatively longer disease of PSP-RS patients of our sample
could also explain the highest accuracy of midbrain area compared to
previous studies (Oba et al., 2005; Quattrone et al., 2008).
The main limitation of the study is the relatively advanced clinical
stage participants included. Other limitations are its retrospective char-
acter, and, although no signiﬁcant differences in disease duration be-
tween groups were found, the different speed of disease progression
andmedian severity stage should be taken into account in the interpre-
tation of the results.
Themain strengths of this study are represented by the use of a stan-
dardized brainMRprotocol to the samepatient population, allowing the
comparison of the diagnostic accuracy of different MRmarkers, and the
inclusion of feasible and time-saving MR techniques that may be easily
applied in a clinical setting.
5. Conclusions
Our study demonstrated, in the samepatient populationwith a clear
clinical diagnosis, that several quantitative brain MRmarkers, provide a
high diagnostic accuracy in the in vivo differential diagnosis between
advanced PSP-RS and PD.
In particular, the evaluation of midbrain area is the most accurate
single diagnostic marker in the differential diagnosis between PSP-RS
and PD (99%), and the Z-test demonstrated that none of the others dif-
fered from each other in discriminating capacity.
The measurement of midbrain area can easily be performed on con-
ventional sagittal MR images whose inclusion in neuroradiological MR
protocols evaluating patients with suspected degenerative parkinson-
ism, makes the routine acquisition of DTI images unnecessary.
Further prospective and multi-center studies on large cohorts of pa-
tients with clinically unclassiﬁable parkinsonism and earlier disease
stages are warranted to conﬁrm our ﬁndings and better deﬁne accuracy
and cut-offs for clinical use.
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